---
title: "From prescription to doorstep: inside a compounded GLP-1 order"
description: "Cold chain, lot tracking, and the 48-hour window that decides whether a patient reorders. The fulfillment pipeline behind every Cuvo-powered brand."
canonical: "https://cuvo.co/blog/glp1-fulfillment-pipeline"
last-updated: "Jun 24, 2026"
---
# From prescription to doorstep: inside a compounded GLP-1 order

By Marcus Oyelaran, VP of Pharmacy Operations. Published Jun 24, 2026. Pharmacy.

A compounded GLP-1 order looks simple from the patient's side: approve the visit, wait a few days, open a cold box on the doorstep. Behind that box sits a regulated relay of provider, pharmacy, cold chain, and carrier, where one broken handoff can spoil a vial or stall a refill. Cuvo runs that relay, and the operational lesson is that the first 48 hours after delivery decide whether a patient starts strong.

Every Cuvo-powered brand sells the same promise: a patient starts online and, days later, a refrigerated package arrives with compounded semaglutide or tirzepatide, ready to use. The brand owns that promise and the marketing around it. Cuvo owns the pipeline that has to deliver it, provider to pharmacy to doorstep, without a temperature excursion, a mislabeled vial, or a lost lot number. Here is that pipeline, stage by stage.

**The order at a glance**
- Medications: Compounded semaglutide and tirzepatide, dispensed by licensed pharmacies
- Cold chain: Refrigerated, 2 to 8 degrees C, end to end
- Prescription rail: Electronic, with EPCS available for controlled categories
- Lab orders: Labcorp and Quest
- Medication markup: 0%, wholesale pass-through
- The window that matters: First 48 hours after delivery

- Stage 1: Provider approves the visit and issues the e-prescription
- Stage 2: Order routes to a licensed pharmacy in the network
- Stage 3: Medication compounded or dispensed, labeled, lot recorded
- Stage 4: Cold-chain packing at 2 to 8 degrees C
- Stage 5: Carrier handoff and delivery
- Stage 6: Arrival and the first 48 hours
- Stage 7: Refill authorization on cadence

## 01. Provider approval and the e-prescription

The pipeline starts with a clinical decision, not a checkout. A provider in Cuvo's network reviews the patient's intake, history, and any required labs, and prescribes a GLP-1 only when it is medically appropriate. Semaglutide and tirzepatide are not controlled substances, so the prescription moves on standard electronic rails rather than the DEA's EPCS track. The same platform carries EPCS for controlled categories a brand may also run, such as testosterone, so the prescribing infrastructure is built to the stricter standard even when a GLP-1 order does not require it.

## 02. Routing to the pharmacy network

Once signed, the prescription routes to a pharmacy in Cuvo's national network. The FDA's compounding framework distinguishes 503A pharmacies, which fill patient-specific prescriptions under state board of pharmacy oversight, from 503B outsourcing facilities, which register with the FDA and produce larger batches. That distinction shifted underneath the whole category: after the FDA declared the semaglutide shortage resolved in February 2025 and tirzepatide in late 2024, routine compounding of copies narrowed, and in April 2026 the FDA proposed removing these drugs from the 503B bulk-compounding list entirely. Cuvo routes each order to a licensed pharmacy operating within the current rules and absorbs the sourcing changes so the brand does not have to track them.

## 03. Compounding, dispensing, and the lot number

At the pharmacy, the medication is compounded or dispensed, filled, and labeled, and two records attach to every unit for the rest of its life. The first is the beyond-use date: per USP General Chapter <797>, a compounded sterile injectable carries a dating window set by how and where it was made, with refrigerated storage extending that window well beyond room temperature. The second is the lot number, the thread that makes a recall possible. State boards of pharmacy require that lot numbers and beyond-use dates be recorded against each prescription, alongside a recall plan that can identify every patient who received an affected lot, in some states within hours. Cuvo's fulfillment records preserve that chain, so a single lot traces to the patients holding it.

## 04. Cold-chain packing and summer shipping

Compounded GLP-1s are temperature-sensitive, so they ship refrigerated at 2 to 8 degrees C. Pharmacies pack them in insulated containers with coolant, gel packs for shorter transits and phase-change materials for longer or hotter routes, and many add a temperature indicator so an excursion is visible on arrival. Summer is the hard case: when a heat wave or a weekend would leave a package baking in a truck or on a porch, the operational answer is often to hold the shipment for a cooler carrier window. A delayed box beats a spoiled one.

> **What Cuvo handles here** The pharmacy network, cold-chain packaging standards, coolant selection, and the shipping calendar sit inside Cuvo's operation. The brand does not choose packaging, decide when a summer hold is warranted, or touch the medication. Cuvo coordinates the pharmacy and the carrier; the brand is told when an order ships and lands, and owns the message the patient reads about it.

## 05. Carrier handoff and delivery

Once sealed, the package leaves the pharmacy's control and enters the carrier's, the least controllable stage in the pipeline and the one most exposed to weather, address errors, and missed deliveries. Cuvo builds the transit window into the plan: pharmacies ship early in the week to avoid weekend layovers, coolant is sized for the expected route and season rather than a best case, and tracking is watched so a stalled package can be reshipped before its dating window closes. The target is simple to state and hard to guarantee: the vial is still between 2 and 8 degrees C when the patient opens the box.

## 06. Arrival and the first 48 hours

Delivery is where most pipelines declare victory. The patient data says otherwise. GLP-1 persistence is weak across the industry: a 2024 analysis in the Journal of Managed Care and Specialty Pharmacy by Gleason and colleagues found roughly a third of commercially insured patients still on therapy at one year, and about 47 percent for semaglutide, with discontinuation heaviest early in treatment. A 2026 Cleveland Clinic study of nearly 8,000 patients who stopped within three to twelve months found cost and side effects were the leading reasons. Early nausea, an uncertain first injection, and a silent inbox are exactly what turn a delivered box into an unopened one.

So the first 48 hours after delivery are the operational hinge of the whole pipeline. A patient who takes a confident first dose, knows which early side effects to expect, and can reach someone with a question reaches week two. One who lets the box sit in the fridge often does not. The pipeline that got the vial to the door is only worth the start it enables.

- An unboxing that reads as clinical, not as a mystery parcel: clear labeling, storage instructions, and a beyond-use date the patient can find
- First-dose guidance, so the first injection is not the patient's first time working it out alone
- Plain information on expected early side effects and when they warrant contacting a provider
- A check-in that opens a real line back to the care team, not a dead-end confirmation email

## 07. Refill authorization

A patient who starts strong reaches the refill, and refills are where a program holds or leaks. Cuvo runs refill authorization as a clinical checkpoint, not an auto-charge: the provider reviews progress, tolerability, and any dose change before the next fill is released, labs are reordered through Labcorp or Quest when the protocol calls for it, and the next cold-chain shipment is scheduled to land before the patient runs out. The brand sees a patient continuing on treatment. Underneath, Cuvo re-ran the same regulated pipeline on cadence.

> **Where the line sits** Cuvo runs the regulated backend end to end: providers, pharmacy, compounding, cold chain, lot tracking, refill authorization, and adverse-event escalation. The brand owns what the patient chose it for: acquisition, the storefront, the unboxing, and non-medical customer care. The operator is never passive here. The parts that build loyalty are theirs, and the parts that carry regulatory and clinical risk are Cuvo's.

## Frequently asked questions

**Q: Who is liable if a shipment melts in transit?**

A: The dispensing pharmacy and Cuvo's fulfillment operation own the cold chain, not the brand. Packages ship with coolant sized to the route and, where used, a temperature indicator; if a shipment arrives outside its 2 to 8 degrees C window or an excursion is flagged, the vial is not dispensed for use and a replacement is arranged. The brand does not adjudicate cold-chain failures and never handles the medication.

**Q: Does the brand ever touch the medication?**

A: No. Compounded semaglutide and tirzepatide are dispensed by licensed pharmacies in Cuvo's network and shipped directly to the patient. The brand owns marketing, the storefront, and non-medical customer care; it does not stock, handle, or fulfill medication, which keeps the regulated supply chain inside licensed hands.

**Q: How are refills authorized?**

A: As a clinical decision, not an automatic renewal. A provider reviews the patient's progress, tolerability, and any dose adjustment before each refill is released, with labs reordered through Labcorp or Quest when the protocol requires them, and Cuvo schedules the next cold-chain shipment to arrive before the current supply runs out.

**Q: What actually happens in the first 48 hours after delivery?**

A: The patient takes a first dose or does not. Cuvo supplies first-dose guidance, expected side-effect information, and a provider to answer dosing questions, while the brand owns the unboxing and welcome experience around it. Research links early support with better persistence, which is why this window gets dedicated attention rather than a single confirmation email.

**Keep reading**
- [DEA extends telemedicine flexibilities through 2026](/blog/dea-telemedicine-flexibilities-2026): How the controlled-substance side of the prescription rail stays legal
- [The 5 best white label telehealth platforms in 2026](/blog/best-white-label-telehealth-platforms): Where this fulfillment model sits in the wider market
- [Provider network vs. hiring your own clinicians for telehealth](/blog/provider-network-vs-hiring-your-own-clinicians): Which clinical model fits a refill-heavy GLP-1 program
- [Cuvo pricing](/pricing): Flat per-consult fee and 0% medication markup, published

*Clinical disclaimer: This article is for informational purposes only and is not medical advice. Prescriptions and treatment decisions, including whether to prescribe a compounded GLP-1, dosing, and refills, are made solely at the discretion of the treating licensed provider and only when medically appropriate. Compounded semaglutide and tirzepatide are dispensed by licensed pharmacies. Compounding rules, including the FDA's treatment of 503A and 503B pharmacies, continue to evolve, and Cuvo routes orders to pharmacies operating within current law. Individual results, storage windows, and shipping timelines vary.*

Canonical page: https://cuvo.co/blog/glp1-fulfillment-pipeline